Kite Pharma, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 58 Posts
1 2 3 4
IBB – Challenging 2016, Recovering 2017 And Resurgence In 2018
Article By: Noah Kiedrowski Tuesday, February 6, 2018 3:12 PM EST
The Biotechnology cohort has finally notched a 52-week high and has made up much of the lost ground during the pummeling from both sides of the political isle during the 2016 presidential race.
In this article: AGN, JNJ, NVO, IBB, REGN, GILD, JUNO, ABBV, KITE
Read
E Ford Model T And Personalized Medicine
Article By: Ketan Desai Monday, December 11, 2017 10:35 AM EST
While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?
In this article: JUNO, KITE, EDIT
Read
Best Sector ETF Of Q3 And Its Top-Performing Stocks
Article By: Sweta Killa Monday, October 2, 2017 3:08 PM EST
The biotech sector led the U.S. stock market higher last quarter with Virtus LifeSci Biotech Clinical Trials ETF topping the list of the best-performing ETFs, logging impressive returns of about 21.4%.
In this article: SGMO, DVAX, INSM, KITE, MYOK, BBC
Read
6 ETF Picks For September
Article By: Zacks Investment Research Wednesday, September 6, 2017 6:44 AM EST
The Euro zone economic growth has looked up this year. The region grew 0.6% sequentially in Q2 following 0.5% expansion in the previous period. Despite this positive sentiment, a rising euro might be a deterrent.
In this article: AOM, DFE, SMH, XBI, KITE, ACWF Also: QQQ, GILD
Read
Biopharmaceuticals Portfolio In A Biotech Bull Market
Article By: Rod Raynovich Tuesday, September 5, 2017 11:08 PM EST
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4.
In this article: BMY, RHHBY, IBB, QQQ, AMGN, BIIB, GILD, XBI, ABBV, KITE, BLUE, FMI
Read
M&A Theme Continues To Boost Biotech Stocks
Article By: Rod Raynovich Wednesday, August 30, 2017 9:30 PM EST
The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and 6.48% over five days to $323.76 approaching its YTD high of $327.34.
In this article: IBB, GILD, XBI, KITE, BLUE Also: BMRN, INCY, SGEN, CLVS, VRTX, AGIO, PTLA
Read
With $12B Deal, Kite Pharma Continues To Soar
Article By: ValueWalk Tuesday, August 29, 2017 12:54 PM EST
Kite's stock has experienced another leap up and to the right. The company's primary drug, a treatment for lymphoma and other blood cancers, is currently seeking regulatory approval in the US and Europe.
In this article: KITE Also: GILD
Read
Deep Purple
Article By: Marvin R Clark Monday, August 28, 2017 10:06 PM EST
Domestic energy stocks were slammed today. Exxon down 0.3% and Chevron down 0.4%. Refiner Valero Energy climbed 1.1 percent.
In this article: CVX, VLO, XOM, AMZN, GILD, WFM, UGA, PSX, KITE Also: AAPL, MSFT, FB, GOOGL
Read
Wells Fargo Sees Little Chance Of Higher Bid For Kite Pharma
Article By: The Fly Monday, August 28, 2017 8:05 PM EST
Gilead and Kite Pharma have announced that the companies have entered into a definitive agreement pursuant to which the former will acquire the latter for $180 per share in cash.
In this article: GILD, JUNO, KITE, BLUE, CLLS
Read
Bluebird Bio Jumps After Gilead Buys Peer Kite Pharma
Article By: The Fly Monday, August 28, 2017 9:12 AM EST
Shares of Bluebird Bio are up 6% in premarket trading to $104.00 after Gilead Sciences announced an agreement to acquire Kite Pharma for $11.9B or $180 per share.
In this article: GILD, BLUE, KITE Also: CLLS, JUNO
Read
Kite Pharma Is Flying High
Article By: Bob Lang Thursday, August 24, 2017 4:59 AM EST
Kite Pharma has been a bright light in a rather dim biotech sector. Just look at its performance since the gap up in June. It has risen a whopping 80% – even the dog days of summer cannot slow it down.
In this article: KITE
Read
Kite Pharma - Chart Of The Day
Article By: Jim Van Meerten Wednesday, August 23, 2017 8:57 PM EST
Since the Trend Spotter signaled a buy on 6/8 the stock gained 55.42%.
In this article: KITE
Read
Kite Pharma (KITE) Q2 Loss Narrower Than Expected, Sales Beat
Article By: Zacks Investment Research Tuesday, August 8, 2017 11:02 AM EST
While Kite’s research and development expenses shot up almost 50% from the year-ago period to $70.9 million in the reported quarter, general and administrative expenses were $41.1 million, up 73.3% from the year-ago period.
In this article: KITE
Read
ETF Winner Of 1H17 And Its Top 5 Stocks
Article By: Sweta Killa Sunday, July 2, 2017 6:00 AM EST
Despite recent turmoil, the technology sector continues to be investors’ hot favorite and is the clear winner so far. ARK Innovation ETF has topped the list of the best-performing ETFs of the first half of 2017, with impressive returns of about 45%.
In this article: KITE, BLUE, FMI, ARKK, SQ, GBTC
Read
BIO 2017 International #1: CAR-T Therapies On Solid Tumors
Article By: Rod Raynovich Thursday, June 22, 2017 11:45 PM EST
CAR-T shows great promise against blood cancers but challenges remain for solid tumors. Bellicum Pharmaceuticals, Bluebird bio, Cellectis SA, Juno Therapeutics, Kite Pharma and Poseida Therapeutics are some of the major companies engaged in CAR-T.
In this article: JUNO, KITE, BLUE, CLLS, BLCM
Read
Late Slide In Tech Mega-Caps Leaves Averages Mixed For Week
Article By: The Fly Saturday, June 10, 2017 10:38 AM EST
Stocks appeared in line for a slight weekly advance until Friday afternoon, when a sharp decline in a number of mega-cap tech stock pushed the Nasdaq down nearly 2.5% at its low point.
In this article: DFT, DHI, DLR, FOR, JWN, M, THO, VZ, CLDR, AMRI, GIII, NLNK, AAPL, AMZN, FRAN, GOOG, MSFT, YHOO, DVAX, JUNO, BABA, FB, AMBA, GLYC, KITE, BLUE, MIK, ANTM, PLAY, RDUS, LOXO, DLTH, HDS
Read
1 to 16 of 58 Posts
1 2 3 4